With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues to evolve. To date, the MS market has accommodated a role for all current therapies due to disease heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each DMT. That said, with each new launch, players in the MS space—both new and established—must assess where their products fit in an increasingly crowded market, especially next-in-class alternatives offering incremental benefits. Meanwhile, competing paradigms of escalation versus early intervention with high-efficacy drugs remain, stoked by the clean clinical profile of Roche/Genentech’s Ocrevus. This national patient-level claims data analysis explores the current DMTs’ positioning, examines line of therapy progression, and assesses persistence and compliance by brand.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Bayer, Biogen, EMD Serono, Genentech / Roche, Mylan, Novartis, Sanofi Genzyme, Teva
Key drugs covered: Aubagio, Avonex, Betaseron, Copaxone / Glatopa / glatiramer acetate, Extavia, Gilenya, Lemtrada, Mavenclad, Mayzent, Ocrevus, Plegridy, Rebif, Tecfidera, Tysabri
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.